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Key Points 
 
 
1. MRD negativity is a predictor for long-term progression-free and overall survival 
independent of the type and line of therapy. 
 
2. MRD negativity confers the greatest prognostic benefit when achieved in the frontline 
setting.  
 
 
 
 
Abstract 
 
 
Minimal residual disease (MRD) negativity, defined as <1 chronic lymphocytic leukemic 
(CLL) cell detectable per 10,000 leukocytes, has been shown to independently predict for 
clinical outcome in patients receiving combination chemoimmunotherapy in the frontline 
setting. However, the long-term prognostic value of MRD status in other therapeutic settings 
remains unclear. Here, we retrospectively analyzed, with up to 18 years follow up, all 
patients at our institution who achieved at least a partial response (PR) with various 
therapies between 1996 and 2007, and received a bone marrow MRD assessment at the 
end of treatment according to the international harmonized approach. MRD negativity 
correlated with both progression-free (PFS) and overall survival (OS) independent of the 
type and line of treatment, as well as known prognostic factors including adverse 
cytogenetics. The greatest impact of achieving MRD negativity was seen in patients 
receiving frontline treatment, with 10-year PFS of 65% vs 10% and 10-year OS of 70% vs 
30% for MRD-negative vs positive patients. Our results demonstrate the long-term benefit of 
achieving MRD negativity regardless of the therapeutic setting and treatment modality, and 
support its use as a prognostic marker for long-term PFS and as a potential therapeutic goal 
in CLL.  
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Introduction 
 
Residual CLL often remain in patients who have achieved a complete remission (CR) as 
defined in the International Workshop on CLL (IWCLL) response criteria.1 The expansion of 
residual CLL cells may lead to eventual disease relapse with the duration of remission 
dependent on the depth of remission and the rate of CLL repopulation. MRD can now be 
reliably detected to a level of 1 CLL cell in 104 leukocytes (0.01%). Although not routinely 
performed in clinical practice, many trials have assessed MRD levels using the flow 
cytometry assay harmonized and validated by the European Research Initiative on CLL.2-4 
 
These trials have shown consistent correlation between post-treatment MRD level and 
therapeutic outcome,5-15 with MRD status demonstrating independent prognostic significance 
in patients treated upfront with chemoimmunotherapy.9,13,14 However, the independent 
prognostic relevance and long-term benefit of MRD negativity in other therapeutic settings, 
such as with chemotherapy-free treatments, remain unclear. Moreover, a direct comparison 
of the clinical impact of MRD negativity between frontline and relapsed/refractory settings 
has not hitherto been undertaken.  
 
For the past 20 years, MRD evaluation has formed an integral part of the response 
assessment for CLL studies at our institution. This resulted in the availability of patients at 
different disease stages with known MRD status following various treatments, many with 
extended follow-up. We herein present an analysis of this historical cohort, to address the 
long-term prognostic value of MRD status across different therapeutic settings and treatment 
modalities.  
 
 
 
Patients and Methods 
 
Study criteria 
 
We retrospectively analyzed all patients at our institution who completed treatment for CLL 
during 1996 to 2007, achieved at least a PR, and received a bone marrow MRD assessment 
within 6 months of treatment completion. Patients who failed to respond or died before 
treatment completion were excluded, as were those who received allogeneic stem cell 
transplantation, since graft-versus-leukemia effect can lead to continued depletion of 
residual disease. Also excluded were patients who subsequently received alemtuzumab for 
consolidation as part of the National Cancer Research Institute (NCRI) CLL207 trial. For 
individuals receiving multiple treatments, the first therapy completed between 1996 and 2007 
was used for analysis. This study was undertaken with approval from our institutional ethics 
committee, and informed consent was obtained from all patients. 
 
MRD and outcome analysis 
 
MRD assessments were carried out using multiparameter flow cytometry according to the 
international harmonized approach.2-4 Assessments performed before 2003 did not 
necessarily contain all the reported markers, but data was included only if it was ascertained 
from the pre-treatment material that a limit of detection of 10-4 CLL cells could be achieved 
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with the available markers. Progression evaluations were made blinded to MRD status, and 
MRD status did not influence treatment duration, except for individuals receiving 
alemtuzumab who were treated until maximum IWCLL and MRD response was attained.  
 
Survival analysis was carried out using SPSS Statistics. OS and PFS were calculated from 
the date of treatment completion to death or clinical progression respectively. Statistical 
significance in time-to-event analyses was evaluated using the univariate log-rank method. 
Multivariate analyses were performed using the Cox proportional-hazards model, and all 
prognostic variables that were routinely assessed and available for % of patients were 
included. 
 
 
 
Results and Discussion 
 
Altogether 536 patients were assessed at our MRD laboratory during the study period, of 
whom 173 received treatment at our institution. Of these, 23 were excluded due to a lack of 
CR/PR, 10 due to the assessment of blood rather than bone marrow MRD, 3 because of 
treatment with allogeneic stem cell transplantation and 4 as a result of subsequent 
enrolment into a consolidation trial (NCRI CLL207). Among the 133 who fulfilled the inclusion 
criteria, 67 received combination chemotherapy or chemoimmunotherapy, 31 received 
single-agent chemotherapy, 7 underwent autologous stem cell transplantation, and 28 were 
treated with chemotherapy-free regimens, mostly with monoclonal antibody therapy. Fifty-
seven received no previous CLL treatment, with the remainder having 1 to 7 prior therapies. 
Fifty-five (41%) were MRD-negative post-treatment, including 46 with CR/CRi and 9 with 
PR/nPR. IWCLL response was evaluated in most cases (78%) by CT imaging. All patients 
with a MRD-negative PR had morphologically clear bone marrow but residual adenopathy. 
The demographic and treatment details are summarized in supplemental Tables 1-2.  
 
With a median follow up of 10.1 years (range 7.8-18.6) among surviving patients, the median 
PFS in MRD-negative (<0.01%) individuals was 7.6 years, compared to 3.3 and 2 years 
respectively in individuals with positive MRD at 0.01-1% and >1% (Figure 1A). The median 
OS was likewise prolonged in MRD-negative patients (10.6 years) compared to MRD-
positive patients (5.3 and 3.6 years respectively for 0.01-1% and >1% MRD; Figure 1B). 
Patients with MRD-negative PR appeared to have outcomes intermediate between patients 
with MRD-negative CR and those with MRD positive CR/PR (supplemental Figure 1). When 
MRD response was considered together with established prognostic factors including age, 
Binet stage, cytopenias, prior treatment and adverse cytogenetics evaluated at the time of 
treatment, as well as treatment modality and IWCLL response, only MRD response and 
adverse cytogenetics were significant for PFS, and only MRD response, age, stage and prior 
treatment were significant for OS on multivariate analysis (Table 1). 
 
Patients receiving both frontline and subsequent treatments derived significant PFS and OS 
benefit from attaining MRD negativity (Figure 1C-D). However, greater long-term benefit was 
seen when MRD negativity was achieved upfront, with 10-year PFS of 65% vs 10% and 10-
year OS of 70% vs 30% for MRD-negative vs positive patients. In comparison, in the 
relapsed/refractory setting the 10-year PFS was 30% vs 0% and 10-year OS was 47% vs 
11% for MRD-negative vs positive patients. The PFS curve for the 23 patients who achieved 
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MRD negativity upfront appears to plateau at 7.7 years, beyond which no clinical relapse 
was observed among the 12 (52%) who remained in remission (Figure 1C). This is similar to 
the PFS plateau reported in the IGHV mutated MRD-negative patients from the MD 
Anderson Cancer Center fludarabine, cyclophosphamide and rituximab (FCR) trial,16 
although in our cohort 1/9 patient with known IGHV status in remission beyond 7.7 years had 
unmutated IGHV. Finally, in patients with del(17p) or del(11q), achievement of MRD 
negativity appeared to partially overcome the poor prognosis associated with their 
cytogenetic aberrations (Figure 1E-F), suggesting that targeting MRD may potentially be of 
value in this patient group.  
 
This is the first study to incorporate different treatment settings and modalities into a single 
multivariate model to evaluate the clinical impact of post-treatment MRD status in CLL. In 
line with IWCLL guidelines,1 bone marrow rather than peripheral blood MRD was reported, 
because bone marrow is considered a more sensitive site for MRD detection than blood 
early after treatment completion, particularly in patients receiving monoclonal antibodies.2 
Our study confirms the independent predictive value of MRD not only in the frontline but also 
in the relapsed/refractory setting, and not only with chemoimmunotherapy but also with 
chemotherapy-free treatments. Extended follow-up of our cohort revealed long-term 
treatment-free remissions among MRD-negative patients, particularly when MRD negativity 
was attained upfront. Hence, our findings support MRD as a prognostic marker for long-term 
PFS. Indeed, the use of MRD as a trial endpoint is currently under active investigation. An 
explanation for the importance of achieving MRD negativity upfront could be that poor 
survival is associated with the development of a resistant genotype (e.g. TP53 mutation), 
which arises or is enriched within residual disease post-therapy.17-19 In patients with 
profound remissions there is a smaller pool of residual cells in which such resistance can 
occur. This underscores the importance of achieving the best possible response with first-
line therapy.  
 
Due to the historical nature of our cohort, IGHV mutational status was not available in every 
patient. Moreover, some therapies in our cohort were historical. However, the significance of 
this study lies in the demonstration that the clinical benefit of MRD negativity was 
independent of the type or line of therapy through which this was achieved. Indeed, the 
median PFS of the MRD-negative and positive patients in our cohort treated with 
chemotherapy-free regimens was significantly different at 4.9 and 1.3 years respectively 
(P=.002). At present, MRD negativity is achieved predominantly through chemotherapy-
containing regimens with considerable toxicity, thus precluding its use in frailer CLL patients. 
Newer agents such as venetoclax can also produce MRD negativity in substantial 
proportions of CLL patients, including in individuals with del(17p).20,21 The prognostic 
significance of MRD with novel treatments will need to be prospectively validated. In future, 
chemotherapy-free combinations may potentially allow MRD eradication with minimal 
toxicity, making MRD negativity a feasible therapeutic goal. 
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Table 1. Univariate and multivariate analysis of post-treatment MRD levels                         
with other parameters of prognostic significance 
 
 
Parameter 
Progression-free Survival Overall Survival 
Univariate 
(Log-Rank) 
P Value 
Multivariate 
(Cox)  
P Value 
Hazard 
Ratio  
(95% CI) 
Univariate 
(Log-Rank) 
P Value 
Multivariate 
(Cox)  
P Value 
Hazard 
Ratio  
(95% CI) 
Age* (60 years) .513 
 
 
.001 .001 2.41 (1.45-4.00) 
Hemoglobin* (110 g/L) .957 
 
 .058 
 
 
Platelet* (100 x 109/L) .001 .983  .034 .168  
Binet stage* (A/B vs C) .005 .870  .001 .018 2.23 (1.14-4.33) 
 
Prior treatment (Y/N) .003 .159  .003 <.001 2.61 (1.61-4.23) 
Treatment type <.001 .265  .004 .886  
IWCLL Response <.001 .545  .001 .585  
MRD level 
(< 0.01 / 0.01-0.1 / 
0.1-1 / > 1%) 
<.001 <.001 2.07  (1.59-2.69) <.001 .002 
1.39  
(1.13-1.70) 
Adverse cytogenetics* 
(del 17p/11q) .024 .013 
2.00 
(1.16-3.45) .051   
 
 
* Age, hemoglobin and platelet count, Binet stage and cytogenetics were assessed at the 
time of treatment initiation.  
 
 Cytogenetic aberrations [del(17p) and/or del(11q)] were evaluated by metaphase 
fluorescence in-situ hybridization (FISH). 
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Figure Legends 
 
 
Figure 1.  Presence of residual disease at the end of treatment predicts for long-term 
PFS and OS independent of prior treatment and cytogenetics. Post-treatment MRD 
levels were obtained within 6 months following the end of treatment by multiparameter flow 
cytometry to a sensitivity of 10-4 (0.01%). A patient was considered MRD negative if the 
MRD level was below the level of detection (i.e. <0.01%). The log-rank P value is displayed, 
and P<.05 is considered statistically significant. (A) PFS according to the level of detectable 
disease at the end of treatment. (B) OS according to the level of detectable disease at the 
end of treatment. (C) PFS according to prior treatment and the MRD status at the end of 
treatment. (D) OS according to prior treatment and the MRD status at the end of treatment. 
(E) PFS according to del(17p) or del(11q) and the MRD status at the end of treatment. (F) 
OS according to del(17p) or del(11q) and the MRD status at the end of treatment. In (E-F), 
cytogenetic aberrations were evaluated by FISH. The balance of patients with del(17p) and 
del(11q) respectively was comparable between the MRD-negative and MRD-positive groups. 
In the MRD-negative del(17p/11q) group, 3/9 patients (33%) had del(17p) while 6/9 patients 
(67%) had del(11q). In the MRD-positive del(17p/11q) group, 6/15 patients (40%) had 
del(17p) while 9/15 patients (60%) had del(11q). MRD-neg, MRD-negative; MRD-pos, MRD-
positive.   
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